14 August 2018

TIKOMED Announce Start of ALS Study at Sahlgrenska University Hospital

VIKEN, Sweden, August 14, 2018 – ​TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases, is delighted to announce that the company today has started its clinical trial (Phase 2a) in Amyotrophic Lateral Sclerosis (ALS ) at Sahlgrenska University Hospital.

Anders Svenson M.D., Chief Medical Officer of TIKOMED, commented, “Today, we present an important milestone, with the start of our first phase 2a clinical trial in ALS at Sahlgrenska University Hospital. We are excited and hope ILB’s unique mechanism of action, triggering self-repair and protection will bring new hope to both patients and caregivers suffering from ALS.”

Anders Kristensson, Chief Executive Officer of TIKOMED, commented, “Today there is no cure for ALS and the available drug treatment consists of medicine slowing the progression. We hope our ILB drug will prove to be a game changer in ALS and for those patients and caregivers impacted by this terrible disease.”

The study is performed at and in collaboration with Sahlgrenska University Hospital, Gothenburg, Sweden. Assoc. Professor Lennart Persson, an expert in ALS, will be principal investigator.15 patients will be treated with ILB during a 4-week period.

DATE
TBA

TIME
TBA

VENUE
TBA

OTHER NEWS

20 August 2018
TIKOMED to initiate ALS clinical trial for which the UK Medicines and Healthcare products Regulatory Agency has granted permission
Viken, August 20th, 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for…
Read More
24 July 2018
TIKOMED is looking for an experienced Project Leader
We are looking for you who are passionate, skilled and with strong track record and…
Read More
5 July 2018
Tikomed granted permission for clinical trial in ALS by the Swedish Medical Product Agency and Ethical Review Board.
Viken, May 28th, 2018 TikoMed, a specialty pharmaceutical company focused on developing therapeutics for treating…
Read More
SEE MORE